Psychological outcomes of dementia risk estimation in MCI patients: Results from the PreDADQoL project.
Alzheimer's disease
anxiety
biomarker
close other
coping
counseling
dementia risk
depression
disclosure
mild cognitive impairment
quality of life
satisfaction with life
Journal
Alzheimer's & dementia : the journal of the Alzheimer's Association
ISSN: 1552-5279
Titre abrégé: Alzheimers Dement
Pays: United States
ID NLM: 101231978
Informations de publication
Date de publication:
01 Oct 2024
01 Oct 2024
Historique:
revised:
05
08
2024
received:
08
05
2024
accepted:
07
08
2024
medline:
1
10
2024
pubmed:
1
10
2024
entrez:
1
10
2024
Statut:
aheadofprint
Résumé
Understanding the impact of biomarker-based dementia risk estimation in people with mild cognitive impairment (MCI) and their care partners is critical for patient care. MCI patients and study partners were counseled on Alzheimer's disease (AD) biomarker and dementia risk was disclosed. Data on mood, quality of life (QoL), and satisfaction with life (SwL) were obtained 1 week and 3 months after disclosure. Seventy-six dyads were enrolled, and two-thirds of the patients opted for biomarker testing. None of the participants experienced clinically relevant depression or anxiety after disclosure. All dyads reported moderate to high QoL and SwL throughout the study. Patients reported more subthreshold depressive symptoms 1 week and lower QoL and SwL 3 months after disclosure. In patients, depression (odds ratio [OR]: 0.76) and anxiety (OR: 0.81) were significant predictors for the decision against biomarker testing. No major psychological harm is to be expected in MCI patients and care partners after dementia risk disclosure. This study is registered in the German clinical trials register (Deutsches Register Klinischer Studien, DRKS): http://www.drks.de/DRKS00011155, DRKS registration number: DRKS00011155, date of registration: 18.08.2017. Patients with mild cognitive impairment (MCI) and study partners were counseled on Alzheimer's disease (AD) biomarker-based dementia risk estimation. About two-thirds of patients opted for biomarker testing and received their dementia risk based on their AD biomarker status. Patients who decided in favor or against CSF biomarker testing differed in psychological features. We did not observe major psychological harm after the dementia risk disclosure. Coping strategies were associated with better subsequent mood and well-being in all participants.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Federal Ministry of Education and Research
Organisme : Ministry of Economy and Competitiveness
Organisme : Network of European Funding for Neuroscience Research
Informations de copyright
© 2024 The Author(s). Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.
Références
Herukka S‐K, Simonsen AH, Andreasen N, et al. Recommendations for CSF AD biomarkers in the diagnostic evaluation of MCI. Alzheimers Dement. 2016;0:387‐403. doi:10.1016/j.jalz.2016.09.009
Johnson KA, Minoshima S, Bohnen NI, et al. Update on appropriate use criteria for amyloid PET imaging: dementia experts, mild cognitive impairment, and education. Alzheimers Dement. 2013;9:e106‐e109. doi:10.1016/j.jalz.2013.06.001
Shaw LM, Arias J, Blennow K, et al. Appropriate use criteria for lumbar puncture and cerebrospinal fluid testing in the diagnosis of Alzheimer's disease. Alzheimers Dement. 2018;14(11):1505‐1521. doi:10.1016/j.jalz.2018.07.220
Lingler JH, Butters MA, Gentry AL, et al. Development of a standardized approach to disclosing amyloid imaging research results in mild cognitive impairment. J Alzheimers Dement. 2016;52:17‐24. doi:10.3233/JAD‐150985
DGN e. V. & DGPPN e. V. S3‐Leitlinie Demenzen. Version XX. 2023. Available from: https://register.awmf.org/de/leitlinien/detail/038‐013
Cognat E, Troussière A‐C, Wallon D, et al. Clinical impact of cerebrospinal fluid biomarkers in mild cognitive impairment diagnosis. Alzheimers Dement. 2017;13:P336‐P337. doi:10.1016/j.jalz.2017.06.060
Rabinovici GD, Gatsonis C, Apgar C, et al. Association of amyloid positron emission tomography with subsequent change in clinical management among Medicare beneficiaries with mild cognitive impairment or dementia. JAMA. 2019;321(13):1286‐1294. doi:10.1001/jama.2019.2000
De Wilde A, Van Der Flier WM, Pelkmans W, et al. Association of amyloid positron emission tomography with changes in diagnosis and patient treatment in an unselected memory clinic cohort: the ABIDE project. JAMA Neurol. 2018;75(9):1062‐1070. doi:10.1001/jamaneurol.2018.1346
Taswell C, Donohue CL, Mastwyk M, et al. Safety of disclosing amyloid imaging results to MCI and AD patients. Am J Geriatr Psychiatry. 2017;25(3):S129. doi:10.1016/j.jagp.2017.01.147
Vanderschaeghe G, Schaeverbeke J, Bruffaerts R, Vandenberghe R, Dierickx K. Amnestic MCI patients’ experiences after disclosure of their amyloid PET result in a research context. Alzheimers Res Ther. 2017;9(1):92. doi:10.1186/s13195‐017‐0321‐3
Lingler JH, Sereika SM, Butters MA, et al. A randomized controlled trial of amyloid positron emission tomography results disclosure in mild cognitive impairment. Alzheimers Dement. 2020;16:1‐8. doi:10.1002/alz.12129
Grill JD, Cox CG, Kremen S, et al. Patient and caregiver reactions to clinical amyloid imaging. Alzheimers Dement. 2017;13:924‐932. doi:10.1016/j.jalz.2017.01.001
Couch E, Ashford MT, Zhang W, Prina M. Psychosocial and behavioral outcomes for persons with cognitive impairment and caregivers following amyloid‐β PET scan disclosure: a systematic review. Alzheimer Dis Assoc Disord. 2023;37:246. doi:10.1097/WAD.0000000000000569
Kim JE, Tamres LK, Orbell SL, et al. “And does that necessarily mean absolutely Alzheimer's?” An analysis of questions raised following amyloid PET results disclosure. Am J Geriatr Psychiatry. 2024;32:45‐54. doi:10.1016/j.jagp.2023.08.005
Shepherd‐Banigan ME, Ford CB, Smith VA, et al. Amyloid‐β PET scan results disclosure and care‐partner emotional well‐being over time. J Alzheimers Dis. 2022;90:775. doi:10.3233/JAD‐220611
De Wilde A, Van Buchem MM, Otten RHJ, et al. Disclosure of amyloid positron emission tomography results to individuals without dementia: a systematic review. Alzheimers Res Ther. 2018;10(1):72. doi:10.1186/s13195‐018‐0398‐3
WHOQOL Group, Harper A, Power M, et al. Development of the World Health Organization WHOQOL‐BREF quality of life assessment. Psychol Med. 1998;28(3):551‐558. doi:10.1017/S0033291798006667
Stites SD, Karlawish J, Harkins K, Rubright JD, Wolk D. Awareness of mild cognitive impairment and mild Alzheimer's disease dementia diagnoses associated with lower self‐ratings of quality of life in older adults. J Gerontol A Biol Sci Med Sci. 2017;72(6):974‐985. doi:10.1093/geronb/gbx100
Pusswald G, Tropper E, Kryspin‐Exner I, et al. Health‐related quality of life in patients with subjective cognitive decline and mild cognitive impairment and its relation to activities of daily living. J Alzheimers Dis. 2015;47(2):479‐486. doi:10.3233/JAD‐150284
dos Santos SB, Rocha GP, Fernandez LL, de Padua AC, Reppold CT. Association of lower spiritual well‐being, social support, self‐esteem, subjective well‐being, optimism and hope scores with mild cognitive impairment and mild dementia. Front Psychol. 2018;9:371. doi:10.3389/FPSYG.2018.00371/BIBTEX
Diener E, Emmons R, Larsen R, Griffin S. Satisfaction with life scale. J Pers Assess. 1985;49:71‐76. doi:10.1111/j.1758‐0854.2010.01035.x
Pavot W, Diener E. Review of the satisfaction with life scale. In: Diener E, ed. Assessing Well‐Being. Vol 39. Social Indicators research Series, Springer, Dordrecht; 2009:101‐117. doi:10.1007/978‐90‐481‐2354‐4_5
Watson D, Clark LA, Tellegen A. Development and validation of brief measures of positive and negative affect: the PANAS scales. J Pers Soc Psychol. 1988;54:1063‐1070.
Breyer B, Bluemke M. Deutsche version der positive and negative affect schedule PANAS (GESIS panel). Zusammenstellung Wissenschaftlicher Items Und Skalen(ZIS). ZIS‐GESIS Leipniz Institute for Social Sciences. 2016. doi:10.6102/zis242
Couch E, Emmanuelle B, Gadbois EA, DePasquale N, Zhang W, Wetle T. “I know that my role is going to change”: a mixed‐methods study of the relationship between amyloid‐β PET scan results and caregiver burden. Aging Clin Exp Res. 2023;35:387‐397. doi:10.1007/s40520‐022‐02314‐6
Garand L, Lingler JH, Deardorf KE, et al. Anticipatory grief in new family caregivers of persons with mild cognitive impairment and dementia. Alzheimer Dis Assoc Disord. 2012;26:159. doi:10.1097/WAD.0B013E31822F9051
Kemper TD, Lazarus RS. Emotion and adaptation. Contemp Sociol. 1992;21:522. doi:10.2307/2075902
Brandtstädter J, Renner G. Tenacious goal pursuit and flexible goal adjustment: explication and age‐related analysis of assimilative and accommodative strategies of coping. Psychol Aging. 1990;5:58‐67. doi:10.1037//0882‐7974.5.1.58
Chao MD, Scott Roberts J, Marteau TM, et al. Health behavior changes after genetic risk assessment for Alzheimer disease: the REVEAL study. Alzheimer Dis Assoc Disord. 2008;100:130‐134. doi:10.1016/j.pestbp.2011.02.012.Investigations
Largent EA, Harkins K, Van Dyck CH, Hachey S, Sankar P, Karlawish J. Cognitively unimpaired adults’ reactions to disclosure of amyloid PET scan results. PLoS One. 2020;15(2):e0229137. doi:10.1371/journal.pone.0229137
Roberts JS, Cupples LA, Relkin NR, Whitehouse PJ, Green RC. Genetic risk assessment for adult children of people with Alzheimer's disease: the risk evaluation and education for Alzheimer's disease (REVEAL) study. J Geriatr Psychiatry Neurol. 2005;18:250‐255. doi:10.1177/0891988705281883
Banningh LJW, Vernooij‐Dassen M, Rikkert MO, Teunisse JP. Mild cognitive impairment: coping with an uncertain label. Int J Geriatr Psychiatry. 2008;23:148‐154. doi:10.1002/gps.1855
McIlvane JM, Popa MA, Robinson B, Houseweart K, Haley WE. Perceptions of illness, coping, and well‐being in persons with mild cognitive impairment and their care partners. Alzheimer Dis Assoc Disord. 2008;22:284‐292. doi:10.1097/WAD.0B013E318169D714
Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on. Alzheimer's Dis. 2011;7:270‐279. doi:10.1016/j.jalz.2011.03.008.The
Morris J, Heyman A, Mohs R, et al. The consortium to establish a registry for Alzheimer's disease (CERAD‐NP). Part 1. Clinical and neuropsychological assessment of Alzheimer's disease. Neurology. 1989;39:1159‐1165.
Alegret M, Espinosa A, Valero S, et al. Cut‐off scores of a brief neuropsychological battery (NBACE) for Spanish individual adults older than 44 years old. PLoS One. 2013;8:e76436. doi:10.1371/journal.pone.0076436
Sheikh JI, Yesavage JA. Geriatric depression scale (GDS) recent evidence and development of a shorter version. Clin Gerontol. 1986;5:165‐1673. doi:10.1300/J018v05n01_09
Kühner C, Bürger C, Keller F, Hautzinger M. Reliability and validity of the Revised Beck Depression Inventory (BDI‐II). Results from German samples. Nervenarzt. 2007;78:651‐656. doi:10.1007/S00115‐006‐2098‐7
Beck AT, Steer RA, Brown G. Beck Depression Inventory–II. APA PsycTests. 1996. doi:10.1037/t00742‐000
Pachana NA, Byrne GJ, Siddle H, Koloski N, Harley E, Arnold E. Development and validation of the geriatric anxiety inventory. Int Psychogeriatr. 2007;19:103. doi:10.1017/S1041610206003504
Markgraf J, Ehlers A. BAI—Beck‐Angst‐Inventar | Testzentrale. Pearson; 2007.
Beck AT, Epstein N, Brown G, Steer RA. An inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Psychol. 1988;56:893‐897. doi:10.1037/0022‐006X.56.6.893
Posner K, Brown GK, Stanley B, et al. The Columbia‐suicide severity rating scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry. 2011;168:1266‐1277. doi:10.1176/appi.ajp.2011.10111704
First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM‐IV Axis I Disorders. Biometrics Research Department, New York State Psychiatric Institute; 1999.
Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7:270‐279. doi:10.1016/j.jalz.2011.03.008
Deuschl G, Maier W, et al. S3‐Leitlinie Demenzen. In Deutsche Gesellschaft für Neurologie, Hrsg. Leitlinien für Diagnostik und Therapie der Neurologie. 2016. doi:10.1007/s00115‐010‐2999‐3
Grill JD, Apostolova LG, Bullain S, et al. Communicating mild cognitive impairment diagnoses with and without amyloid imaging. Alzheimers Res Ther. 2017;9:35. doi:10.1186/S13195‐017‐0261‐Y
Livingston G, Sommerlad A, Orgeta V, et al. Dementia prevention, intervention, and care. Lancet North Am Ed. 2017;390:2673‐2734. doi:10.1016/S0140‐6736(17)31363‐6
Visser PJ, Wolf H, Frisoni G, Gertz H‐J. Disclosure of Alzheimer's disease biomarker status in subjects with mild cognitive impairment. Biomark Med. 2012;6:365‐368. doi:10.2217/bmm.12.58
Schwegler C, Schmitz‐Luhn B, Romotzky V, et al. Predementia counseling. GeroPsych. 2023;36(4):203‐214. doi:10.1024/1662‐9647/A000313
Vos SJB, Verhey F, Frölich L, et al. Prevalence and prognosis of Alzheimer's disease at the mild cognitive impairment stage. Brain. 2015;138:1327‐1338. doi:10.1093/brain/awv029
Mitchell AJ, Shiri‐Feshki M. Rate of progression of mild cognitive impairment to dementia—meta‐analysis of 41 robust inception cohort studies. Acta Psychiatr Scand. 2009;119:252‐265. doi:10.1111/j.1600‐0447.2008.01326.x
Mitchell AJ, Shiri‐Feshki M. Temporal trends in the long term risk of progression of mild cognitive impairment: a pooled analysis. J Neurol Neurosurg Psychiatry. 2008;79:1386‐1391. doi:10.1136/jnnp.2007.142679
Jack CR, Knopman DS, Jagust WJ, et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013;12:207‐216. doi:10.1016/S1474‐4422(12)70291‐0
Genske A. Gesundheit und Selbstbestimmung. Voraussetzungenu nd Folgen der Einwilligungs(un)fähigkeit von Patienten. Vol 23. Springer; 2020. doi:10.1007/978‐3‐662‐61140‐1
Mejia AM, Smith GE, Wicklund M, Armstrong MJ. Shared decision making in mild cognitive impairment. Neurol Clin Pract. 2019;9:160. doi:10.1212/CPJ.0000000000000576
Garcia‐Retamero R, Cokely ET. Designing visual aids that promote risk literacy: a systematic review of health research and evidence‐based design heuristics. Hum Factors. 2017;59:582‐627. doi:10.1177/0018720817690634
Garcia‐Retamero R, Galesic M. Transparent Communication of Health Risks: Overcoming Cultural Differences. Springer; 2013. doi:10.1007/9781461443582
Lipkus IM. Numeric, verbal, and visual formats of conveying health risks: suggested best practices and future recommendations. Med Decis Making. 2007;27(5):696‐713. doi:10.1177/0272989X07307271
Gigerenzer G, Gaissmaier W, Kurz‐Milcke E, Schwartz LM, Woloshin S. Helping doctors and patients make sense of health statistics. Psychol Sci Public Interest. 2007;8(2):53‐96. doi:10.1111/j.1539‐6053.2008.00033.x
Fagerlin A, Ubel PA, Smith DM, Zikmund‐Fisher BJ. Making numbers matter: present and future research in risk communication. Am J Health Behav. 2007;31(Suppl 1):47‐56. doi:10.5555/AJHB.2007.31.SUPP.S47
Rostamzadeh A, Schwegler C, Gil‐Navarro S, et al. Biomarker‐based risk prediction of Alzheimer's disease dementia in mild cognitive impairment: psychosocial, ethical, and legal aspects. J Alzheimers Dis. 2021;80:601‐617. doi:10.3233/JAD‐200484
Henrich G, Herschbach P. Questions on life satisfaction (FLZM)—a short questionnaire for assessing subjective quality of life. Eur J Psychol Assess. 2000;16(3):150‐159. doi:10.1027//1015‐5759.16.3.150
Flick U. Das Episodische Interview. In: Oelerich G, Otto HU, eds. Empirische Forschung und Soziale Arbeit. VS Verlag für Sozialwissenschaften. 2011. doi:10.1007/978‐3‐531‐92708‐4_17
Creswell J, Creswell JW. Qualitative Inquiry and Research Design: Choosing Among Five Approaches. 2nd ed. Sage; 2007.
Vasileiou K, Barnett J, Thorpe S, Young T. Characterising and justifying sample size sufficiency in interview‐based studies: systematic analysis of qualitative health research over a 15‐year period. BMC Med Res Method. 2018;18(1):148. doi:10.1186/s12874‐018‐0594‐7
Selting M, Auer P, Barth‐Weingarten D, et al. A system for transcribing talk‐in‐interaction: GAT 2 translated and adapted for English by Elizabeth Couper‐Kuhlen and Dagmar Barth‐Weingart. Gesprächsforschung ‐ Online Zeitschrift zur verbalen Interaktion. 2011;12:1‐51.
Deppermann A. Gespräche analysieren. Eine Einführung. 4th ed. Springer; 2008.
Bailly N, Joulain M, Hervé C, Alaphilippe D. Coping with negative life events in old age: the role of tenacious goal pursuit and flexible goal adjustment. Aging Ment Health. 2012;16:431‐437. doi:10.1080/13607863.2011.630374
Günak MM, Barnes DE, Yaffe K, Li Y, Byers AL. Risk of suicide attempt in patients with recent diagnosis of mild cognitive impairment or dementia. JAMA Psychiatry. 2021;78:659‐666. doi:10.1001/JAMAPSYCHIATRY.2021.0150
Christensen KD, Karlawish J, Roberts JS, et al. Disclosing genetic risk for Alzheimer's dementia to individuals with mild cognitive impairment. Alzheimers Dement. 2020;6:e12002. doi:10.1002/trc2.12002
Bélanger E, D'Silva J, Carroll MS, et al. Reactions to amyloid PET scan results and levels of anxious and depressive symptoms: CARE IDEAS study. Gerontologist. 2023;63:71. doi:10.1093/GERONT/GNAC051
Smedinga M, Tromp K, Schermer MHN, Richard E. Ethical arguments concerning the use of Alzheimer's disease biomarkers in individuals with no or mild cognitive impairment: a systematic review and framework for discussion. J Alzheimers Dis. 2018;66:1309‐1322. doi:10.3233/JAD‐180638
Vanderschaeghe G, Dierickx K, Vandenberghe R. Review of the ethical issues of a biomarker‐based diagnoses in the early stage of Alzheimer's disease. J Bioeth Inq. 2018;15(2):219‐230. doi:10.1007/s11673‐018‐9844‐y
Holland JC, Andersen B, Breitbart WS, et al. Distress management: clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2013;11(2):190‐209. doi:10.6004/jnccn.2013.0027
Holland JC, American Cancer Society Award lecture. Psychological care of patients: psycho‐oncology's contribution. J Clin Oncol. 2003;21:253s‐265s. doi:10.1200/JCO.2003.09.133
Janhsen A, Golla H, Romotzky V, Woopen C. Spiritualität im höheren Lebensalter als dynamische Alter(n)saufgabe [Spirituality in old age as dynamic aging task]. Z Gerontol Geriatr. 2019;52(4):359‐364. doi:10.1007/s00391‐018‐1391‐y
Wimo A, Wetterholm AL, Mastey V, et al. Evaluation of the resource utilization and caregiver time in Anti‐dementia drug trials ‐ a quantitative battery. In: Wimo A, Jonsson B, Karlsson G, Winblad B (Eds.), The Health Economis of Dementia, John Wiley & Sons, London. 1998; pp. 465499